• LAST PRICE
    0.6211
  • TODAY'S CHANGE (%)
    Trending Down-0.0079 (-1.2481%)
  • Bid / Lots
    0.6200/ 15
  • Ask / Lots
    0.6570/ 20
  • Open / Previous Close
    0.6300 / 0.6290
  • Day Range
    Low 0.6113
    High 0.6440
  • 52 Week Range
    Low 0.5100
    High 2.3000
  • Volume
    166,547
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.62895
TimeVolumeBLRX
09:32 ET11430.63
09:50 ET1470.630001
09:59 ET1000.64
10:01 ET10000.6201
10:17 ET50000.62
10:28 ET30000.62025
10:32 ET42500.6299
10:55 ET4870.6202
10:57 ET41000.6299
11:00 ET50000.6299
11:02 ET20000.62286
11:04 ET2220.6299
11:08 ET2220.6211
11:13 ET80310.63
11:15 ET81000.63
11:42 ET16000.625
11:58 ET120000.63
12:03 ET1000.6254
12:16 ET3000.6255
12:34 ET7720.629999
12:39 ET4380.629447
01:15 ET1000.6255
01:17 ET10000.6256
01:21 ET74770.62
01:37 ET11000.6113
01:39 ET1750.6114
01:46 ET3500.6115
01:48 ET35000.62
01:50 ET25000.6199
02:00 ET27030.62
02:04 ET1000.63
02:06 ET30000.63
02:22 ET20000.6299
02:26 ET30000.6201
02:42 ET3150.6201
03:03 ET26500.63
03:14 ET32000.6299
03:34 ET5000.627
03:38 ET167040.63
03:45 ET3680.63
03:48 ET20000.63
03:54 ET534540.644
03:57 ET5000.633
03:59 ET11910.6211
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBLRX
BioLine RX Ltd
54.9M
-0.8x
---
United StatesKRON
Kronos Bio Inc
57.3M
-0.5x
---
United StatesLVTX
LAVA Therapeutics NV
45.2M
-1.9x
---
United StatesATRA
Atara Biotherapeutics Inc
55.0M
-0.2x
---
United StatesKZR
Kezar Life Sciences Inc
41.6M
-0.4x
---
United StatesARMP
Armata Pharmaceuticals Inc
82.3M
-1.2x
---
As of 2024-09-14

Company Information

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Contact Information

Headquarters
Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
Phone
---
Fax
---

Executives

Chairman of the Board
Aharon Schwartz
Chief Executive Officer
Philip Serlin
Chief Financial Officer
Mali Zeevi
Vice President - Development
Ella Sorani
Vice President-Clinical & Medical Affairs
Abi Vainstein-Haras

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$54.9M
Revenue (TTM)
$11.7M
Shares Outstanding
80.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.46
EPS
$-0.76
Book Value
$0.18
P/E Ratio
-0.8x
Price/Sales (TTM)
4.7
Price/Cash Flow (TTM)
---
Operating Margin
-391.76%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.